SBIR/STTR Research Award

A mechanism-based computational toolkit to optimize age-specific pediatric pulmonary drug delivery

Award identifier f4f279f8354d0411ef06e75b0ddc3f5004f01101add2c65b134145c824226e21Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,927

Program and phase

SBIR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CFD Research Corporation
Proposal award date
2020-05-18
Contract end date
2021-04-30
UEI
V3KCP1HNFM33
Solicitation number
PAR17-199
Topic code
NICHD

Research abstract

A mechanism-based computational toolkit to optimize age-specific pediatric pulmonary drug delivery Project Summary/Abstract: The selection of the most age-appropriate combination of drug, device, and interface is critical for the effective administration of any prescribed therapy. This is especially relevant in pediatric cases of respiratory disorders that require inhalation therapy. However, in spite of all the modern advancements in inhalation therapies, the fraction of drugs reaching the lungs for maximal therapeutic effects remains low while increasing the dose causes an increase in systemic concentration and subsequent toxicity. The lack of approved age-appropriate drug/device combinations has been limited by experimental constraints in children and the plasticity of pediatric airway structures that continuously evolves from birth to adulthood, influencing airflow dynamics and respiratory mechanics. Motivated by such shortcomings, which cannot be solved by experimental strategies alone, we propose to develop a novel multiscale computational toolkit to simulate deposition, dissolution, absorption, transport, clearance, and actions of inhaled drug products. The core of this toolkit will be an integral framework of computational fluid dynamics (CFD) and whole-body physiology-based pharmacokinetic (PBPK) models, specific to selected age groups. In Phase I, we will (1) develop image-based and anatomically-faithful 3D CFD models of pediatric airway geometry to calculate age-, drug-, and device-specific deposition patterns; (2) extend the CFD models to account for various physiological and pathological settings, such as constriction of airway geometry; and (3) integrate CFD deposition models with PBPK models to estimate systemic concentration of the inhaled drugs. This workflow, in collaboration with Department of Pediatrics, Pulmonology Division at the University of Arkansas College of Medicine, and Department of Radiology at Duke University, will primarily focus on modeling two test subjects for corticosteroid inhalation using two commonly used pediatric inhalation devices. In Phase II, we will further improve our computational tools by model validation on additional pediatric age-groups, drugs and drug combinations, and other pediatric inhalation devices, such as, nebulizers and soft mist inhalers. Our goal of using these computational strategies is to develop a product that will aim to facilitate drug development by identifying key biopharmaceutical factors affecting efficacy and safety of inhaled drugs that help guide age-appropriate dosing, device, and interface selection to better inform clinical practice. The final deliverable will be a commercial quality software package with graphical and instant response abilities to estimate regional and global deposition of inhaled drugs in the human respiratory tract and their fate through its appearance in the systemic blood until eliminated from the body. The software with pre-loaded test cases will be made available at no cost to NIH/FDA researchers for evaluation and testing.Project Narrative: The novel respiratory inhalation framework proposed in this project will provide an efficient, accurate and validated computational platform to virtually test, design, and develop inhaled drug products by investigating interactions between pulmonary delivery systems and the age-specific pediatric anatomical and physiological systems at multiple scales. Applications of the proposed computational tool will reveal key aspects affecting the fate of pediatric administered drugs as well as suggesting guidelines for age-specific dose calculations in diseased states. The long term implications for the application of our developed computational tool for the entire upper and lower airways coupled with other major organs will aid in the unmet need of suggesting and standardizing pediatric inhaled drug doses and devices to deliver the most effective therapy and has the potential to change the current approach to management.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

947 SBIR/STTR records share this UEI (1987–2026). Reported award amounts total $350,893,199. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Health and Human Services, National Science Foundation, Department of Commerce, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.